Johnson & Johnson Consumer Health Presents New Data on Skincare for Cancer Patients at the American Academy of Dermatology VMX 2021
|
SKILLMAN, N.J., April 23, 2021 /PRNewswire/ -- Johnson & Johnson Consumer Health today presented findings from one of the first clinical studies examining a daily skincare regimen as adjunctive therapy for cancer patients at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021. The study shows a daily Avena Sativa (Oat) skincare regimen provided a significant improvement in xerosis and pruritus (dry skin and itch) for adult patients undergoing systemic oncology treatments, indicating Aveeno Restorative Skin Therapy is safe and effective for the management of mild-to-moderate itch and/or dry skin related to systemic oncology treatments in adults. "The ultimate goal of cancer therapy is to save lives, which often involves taking an aggressive approach to treatment that may lead to side effects, including degradation of the skin barrier," said Caroline Tillett, Global Head R&D, Johnson & Johnson Consumer Health. "Johnson & Johnson Consumer Health is committed to providing therapeutic options to support the whole patient's needs with safe and effective over-the-counter solutions. We are pleased to present the results from among the first clinical studies examining a daily over-the-counter skincare regimen showing significant improvement for cancer patients' skin." Patients enrolled in the study reported common side effects of mild-to-moderate xerosis (µ=1.5) and pruritus (µ=0.9) related to their cancer treatment. Patients used an Avena Sativa Skincare Regimen for five weeks, which included:
After five weeks, significant improvements (p<0.05) in xerosis (µ=0.5) and pruritus (µ=0.4) were observed according to dermatologist reported Common Terminology Criteria Adverse Events (CTCAE) scoring and Patient Reported Outcomes Common Terminology Criteria Adverse Events (PROCTCAE) scoring. The regimen was well tolerated and no serious product-related adverse events were observed. Patients also reported significant improvements (p<0.05) in skin moisture with the regimen. They perceived significant improvements in their Quality of Life as measured by Skindex-16 scores including their symptoms, emotional, and functional impact. The Role of the Skin Barrier in Cancer Treatment Side Effects Cancer treatment with kinase inhibitors often results in skin-related side effects, also known as Cutaneous Adverse Drug Reactions (CADRs), which can significantly impact patients' quality of life. Examples of CADRs are skin inflammation, infections, itch, and other symptoms, and are frequent following administration of Epidermal Growth Factor Receptor inhibitors (EGFRis). In a Johnson & Johnson Consumer Health and Janssen Pharmaceutical Companies of Johnson & Johnson analysis examining the effects of eight EGFRis and Vascular Endothelial Growth Factor Receptor inhibitors (VEGFRis) (3, 10, 30, 100nM) on human keratinocytes in a novel 3D micro-skin tissue culture model, results demonstrated that cancer treatment can directly impact cell growth and differentiation on the surface of the skin. "The skin barrier is greatly impacted by certain cancer treatments. As the skin cells normal programming is altered, the skin barrier is damaged, allowing water to escape more easily and irritants to more easily penetrate the skin," said Dr. Georgios Stamatas, Research Associate Director and Fellow, Johnson & Johnson Consumer Health. "Johnson & Johnson Consumer Health and Janssen Pharmaceutical Companies of Johnson & Johnson have shown with this latest research that we can significantly improve mild-to-moderate skin-related side effects with topical solutions, helping patients focus on their cancer treatment." In a full thickness reconstructed human epidermis (RHE) model a decrease in trans-epidermal water loss (TEWL) rate was observed, indicating the skin barrier was compromised. The study showed that topical treatment of the RHE with emollient formulations during EGFRi treatment can reduce, or even completely inhibit, the TEWL increase resulting from treatment with EGFRis. The study showed that topical emollients can help improve skin barrier damage and subsequent skin irritations. Access to all Johnson & Johnson Consumer Health accepted studies and author videos will be available through the AAD VMX portal for AAD registrants. About the Consumer Health business of Johnson & Johnson At Johnson & Johnson Consumer Health, we are driven to improve the personal health of people everywhere. Our differentiated portfolio of iconic brands, including Tylenol®, Zarbee's®, Neutrogena®, Aveeno®, Listerine®, OGX®, and Johnson's®, delivers life-enhancing, first-to-market innovation. By combining the power of science with meaningful human insights and digital-first thinking, we help more than 1.2 billion people live healthier lives every day, from their very first day.
SOURCE Johnson & Johnson |
View original content: